ClinicalTrials.gov
ClinicalTrials.gov Menu

Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index (SALIVENDO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01223157
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : April 28, 2011
Sponsor:
Information provided by:
University Hospital, Bordeaux

Brief Summary:
Up till now, the evaluation of the endocannabinoid system (ECS) in humans needs invasive procedures. The investigators managed in the lab to determine the levels of endocannabinoids in a small number of subjects. The aim of the study is to confirm that salivary is a useful tool to evaluate the activity of the ECS both in normal weight and obese subjects that are characterised by a hyperactivity of the system. Therefore, the first objective of the study is to compare the fasting level of salivary anandamide between 12 obese patients and 12 normal weight subjects.

Condition or disease Intervention/treatment Phase
Obesity Biological: Biological data Not Applicable

Detailed Description:
The prevalence of obesity keeps increasing in industrialized countries. However, efficient treatments of this chronic disease are still lacking. A better understanding of the systems that regulate energy balance and eating behavior is mandatory to better understand the disease and find appropriate treatments. The endocannabinoid system (ECS) which comprises cannabinoid receptors, such as CB1 and CB2, endogenous ligands (named endocannabinoids) and specific biosynthetic and degradative pathways is a key system in the regulation of energy balance and obesity. Obesity is characterised by an hyperactivity of the system both in animal and humans. Moreover, the activity of the ECS is influenced by feeding status although only one study has only been performed in humans. The investigation of the ECS in humans needs invasive procedure (blood sampling or adipose or liver biopsy). The aim of our study is to evaluate a new tool for the ECS evaluation in humans i e the determinations of saliva concentration of endocannabinoids both in normal weight and obese subjects before and after food intake. Blood and saliva sampling will be performed after an overnight fast, one hour before, just before and one hour after a lunch in12 normal weight subjects and 12 obese characterised with anthropometric (Weight, height, BMI (Body Mass Index), waist circumference, blood pressure) and metabolic (glycaemia, insulin, lipid profile, liver profile) evaluations. The endocannabinoids concentrations will be measured with mass spectrometry in blood and saliva and gut hormones (PYY (peptide YY) and ghrelin) will be measured in plasma.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index
Study Start Date : October 2010
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Arm Intervention/treatment
Experimental: Obese patients Biological: Biological data
Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.

Experimental: Normal weight subjects Biological: Biological data
Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.




Primary Outcome Measures :
  1. Anandamide(AEA)concentration [ Time Frame: Saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch ]
    The primary outcome will be the difference of fasting saliva anandamide (AEA) concentration between obese and normal weight subjects.


Secondary Outcome Measures :
  1. 2-AG( 2 arachidonoylglycerol), OEA (oleoylethanolamide), PEA (palmitoyléthanolamide) concentrations [ Time Frame: Saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch ]
    to study fasting saliva concentration of 2-AG (2 arachidonoylglycerol), OEA (oleoylethanolamide), PEA(palmitoyléthanolamide) between obese and lean subjects

  2. Food intake influence on saliva endocannabinoids [ Time Frame: Saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch ]
    To study the effects of food intake on the levels of saliva endocannabinoids both in normal weight and obese subjects

  3. Plasma endocannabinoids level [ Time Frame: Blood sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch ]
    To study the effects of food intake on the levels of plasma endocannabinoids both in normal weight and obese subjects

  4. Correlation between saliva and plasma endocannabinoids [ Time Frame: Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch ]
    To look for a correlation between saliva and plasma endocannabinoids

  5. Relationship between saliva or plasma endocannabinoids and gut hormones [ Time Frame: Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch ]
    To look for a relationship between saliva or plasma endocannabinoids and gut hormones



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Obese patients :

  • Age between 18 and 65 yrs
  • BMI (Body Mass Index) > 30 kg/m²
  • Signed inform Consent before any investigation related to the study
  • No smoker

Normal weight subjects :

  • Age between 18 and 65 yrs
  • BMI between 18 and 25 kg/m²
  • Signed inform Consent before any investigation related to the study
  • No smoker

Exclusion Criteria:

  • treatments that could interfere with the endocannabinoid system (anxiolytics, anticonvulsivants, antidepressants drugs)
  • pregnancy, breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01223157


Locations
France
Service of Endocrinology, Diabetology, metabolic diseases - Hôpital du Haut Lévêque - CHU de BORDEAUX
Bordeaux, France
Sponsors and Collaborators
University Hospital, Bordeaux
Investigators
Principal Investigator: Blandine GATTA, Dr CHU Bordeaux

Responsible Party: Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT01223157     History of Changes
Other Study ID Numbers: CHUBX 2010/14
First Posted: October 18, 2010    Key Record Dates
Last Update Posted: April 28, 2011
Last Verified: April 2011

Keywords provided by University Hospital, Bordeaux:
obesity
endocannabinoids